Shared on10 Sep 25Fair value Decreased 15%
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.
Shared on19 Aug 25Fair value Decreased 13%
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 37.1x to 41.5x.
Shared on09 Apr 25Fair value Increased 14%
AnalystConsensusTarget has increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 56.0x to 37.1x and decreased shares outstanding growth rate from 0.2% to 0.1%.